

the applicant from the Director of the office of Device Evaluation, CDRH.

A summary of the safety and effectiveness data on which CDRH based its approval is on file in the Dockets Management Branch (address above) and is available from that office upon written request. Requests should be identified with the name of the device and the docket number found in brackets in the heading of this document.

Opportunity for Administrative Review

Section 515(d)(3) of the act (21 U.S.C. 360e(d)(3)) authorizes any interested person to petition, under section 515(g) of the act, for administrative review of CDRH's decision to approve this application. A petitioner may request either a formal hearing under part 12 (21 CFR part 12) of FDA's administrative practices and regulations or a review of the application and CDRH's action by an independent advisory committee of experts. A petition is to be in the form of a petition for reconsideration under § 10.33(b) (21 CFR 10.33(b)). A petitioner shall identify the form of review requested (hearing or independent advisory committee) and shall submit with the petition supporting data and information showing that there is a genuine and substantial issue of material fact for resolution through administrative review. After reviewing the petition, FDA will decide whether to grant or deny the petition and will publish a notice of its decision in the Federal Register. If FDA grants the petition, the notice will state the issue to be reviewed, the form of the review to be used, the persons who may participate in the review, the time and place where the review will occur, and other details.

Petitioners may, at any time on or before August 7, 1996, file with the Dockets Management Branch (address above) two copies of each petition and supporting data and information, identified with the name of the device and the docket number found in brackets in the heading of this document. Received petitions may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday.

This notice is issued under the Federal Food, Drug, and Cosmetic Act (secs. 515(d), 520(h) (21 U.S.C. 360e(d), 360j(h))) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Director, Center for Devices and Radiological Health (21 CFR 5.53).

Dated: June 21, 1996.
Joseph A. Levitt,
Deputy Director for Regulations Policy, Center for Devices and Radiological Health.
[FR Doc. 96-17235 Filed 7-5-96; 8:45 am]

BILLING CODE 4160-01-F

National Institutes of Health

National Cancer Institute; Notice of Meeting

Pursuant to Public Law 92-463, notice is hereby given of a meeting of the President's Cancer Panel.

The meeting will be open to the public as indicated below, with attendance by the public limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below.

The meeting will be closed in accordance with the provisions set forth in sec. 552b(c)(9), Title 5, U.S.C. for discussion of future meetings and preparation of the annual report to the President. These discussions could disclose information, the premature disclosure of which would be likely to significantly frustrate implementation of proposed action the Panel may plan to take.

Carole Frank, the Committee Management Officer, National Cancer Institute, Executive Plaza North, Room 630M, 6130 Executive Blvd., MSC 7405, Bethesda, MD 20891-7405 (301-496-5708) will provide a summary of the meeting and the roster of committee members upon request. Other information pertaining to the meetings may be obtained from the contact person indicated below.

Committee Name: President's Cancer Panel.

Date: July 29-30, 1996.

Place: Fred Hutchinson Cancer Center, Stuart Auditorium, First Hill, 1124 Columbia Street, Seattle, WA 98104.

Closed: July 29, 1996—7 p.m. to 10 p.m.

Agenda: Planning session to discuss future meetings and preparation of the mandatory annual report of the Chairman to the President.

Open: July 30, 1996—8:30 a.m. to 5:00 p.m.
Agenda: Managed Care's Role in the War on Cancer. Where are we today? Existing problems for cutting edge clinical research in today's environment.

Contact Person: Dr. Maureen O. Wilson, Executive Secretary, National Cancer Institute, NIH, Building 31, Room 4B43, Bethesda, MD 20892, (301) 496-1148.

(Catalog of Federal Domestic Assistance Program Numbers: 93:393, Cancer Cause and Prevention Research; 93:394, Cancer Detection and Diagnosis Research; 93:395, Cancer Treatment Research; 93:396, Cancer

Biology Research; 93:397, Cancer Centers Support; 93:398, Cancer Research Manpower; 93:399, Cancer Control.)

Dated: July 1, 1996.

Susan K. Feldman,
Committee Management Officer, NIH.
[FR Doc. 96-17209 Filed 7-5-96; 8:45 am]

BILLING CODE 4140-01-M

National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. appendix 2), notice is hereby given of the following National Institute of Allergy and Infectious Diseases Special Emphasis Panel (SEP) meeting:

Name of SEP: Unsolicited AIDS Related Career Award, Conference and Supplement Applications

Date: July 26, 1996

Time: 8:30 a.m.

Place: Doubletree Hotel, Rockville Room, 1750 Rockville Pike, Rockville, MD 20852, (301) 468-1100.

Contact Person: Dr. Paula Strickland, Scientific Review Adm., 6003 Executive Boulevard, Solar Bldg., Room 4C02, Bethesda, MD 20892-7610, (301) 402-0643.

Purpose/Agenda: To evaluate grant applications.

The meeting will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Programs Nos. 93:855, Immunology, Allergic and Immunologic Diseases Research; 93:856, Microbiology and Infectious Diseases Research, National Institutes of Health.)

Dated: July 1, 1996.

Susan K. Feldman,
Committee Management Officer, NIH.
[FR Doc. 96-17210 Filed 7-5-96; 8:45 am]

BILLING CODE 4140-01-M

National Institute of Environmental Health Sciences; Notice of a Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. appendix 2), notice is hereby given of the following National Institute of Environmental Health Sciences Special Emphasis Panel (SEP) meeting:

Name of SEP: The Use of Transgenic Model Systems in Molecular Toxicology.